Pfizer Hopes To Convince FDA With Event-Free Survival Data For Mylotarg
Executive Summary
US agency usually uses endpoint of overall survival to assess acute myeloid leukemia drugs; Mylotarg initially garnered accelerated approval in 2000, but was withdrawn when a confirmatory trial failed to show a clinical benefit. Now it's back before the Oncologic Drugs Advisory Committee.
You may also be interested in...
Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update
Update of 2007 guidance includes discussion on use of newer endpoints and clarifies that oncology endpoints can serve different purposes.
Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication
Agency's Oncologic Drugs Advisory Committee had only discussed gemtuzumab as a treatment for adults with acute myeloid leukemia at its July meeting, but labeling includes a pediatric claim based on a 29-patient trial; drug returns to the US market after being withdrawn in 2010 for failure to confirm clinical benefit.
Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement
Oncologic Drugs Advisory Committee votes 6-1 that benefits of Pfizer's Mylotarg outweigh risks, positioning drug for return to market after being withdrawn in 2010; vote could also open door for future acute myeloid leukemia products to use event-free survival as endpoint.